| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/J.1742-1241.2008.01735.X |
| P8608 | Fatcat ID | release_vlrscauunvgmnbo6wzfvpwuhq4 |
| P932 | PMC publication ID | 2324208 |
| P698 | PubMed publication ID | 18373615 |
| P5875 | ResearchGate publication ID | 5478257 |
| P2093 | author name string | R Sanchez | |
| A Pikalov | |||
| B X Carlson | |||
| C Momah | |||
| D J Muzina | |||
| J M Eudicone | |||
| R D McQuade | |||
| R N Marcus | |||
| P2860 | cites work | A 20-month, double-blind, maintenance trial of lithium versus divalproex in rapid-cycling bipolar disorder | Q42672419 |
| Prevalence of obesity and weight change during treatment in patients with bipolar I disorder | Q43642752 | ||
| Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors | Q44028935 | ||
| Treatment of bipolar I rapid cycling patients during dysphoric mania with olanzapine | Q44156690 | ||
| Quetiapine in the treatment of rapid cycling bipolar disorder. | Q44247110 | ||
| Obesity as a correlate of outcome in patients with bipolar I disorder | Q44265285 | ||
| Olanzapine in the acute treatment of bipolar I disorder with a history of rapid cycling | Q44266760 | ||
| A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder | Q44403599 | ||
| A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania | Q44565868 | ||
| In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function | Q44716841 | ||
| Response to clozapine of rapid cycling versus non-cycling patients with a history of mania | Q44957587 | ||
| Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial | Q46681464 | ||
| Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study | Q46886132 | ||
| Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine | Q46921511 | ||
| A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. | Q47208132 | ||
| Quetiapine monotherapy in the treatment of patients with bipolar I or II depression and a rapid-cycling disease course: a randomized, double-blind, placebo-controlled study | Q48466826 | ||
| Adequacy of treatment received by diagnosed and undiagnosed patients with bipolar I and II disorders. | Q51907203 | ||
| Treatment of Refractory Rapid Cycling Bipolar Disorder With Risperidone | Q57612984 | ||
| Clozapine prophylaxis in rapid cycling bipolar disorder | Q67822230 | ||
| A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group | Q28139401 | ||
| A Double-Blind, Placebo-Controlled, Prophylaxis Study of Lamotrigine in Rapid-Cycling Bipolar Disorder | Q29394100 | ||
| Phenomenology of rapid-cycling bipolar disorder: data from the first 500 participants in the Systematic Treatment Enhancement Program | Q30968143 | ||
| Comparison of rapid-cycling and non-rapid-cycling bipolar I manic patients during treatment with olanzapine: analysis of pooled data | Q30970834 | ||
| New data on the use of lithium, divalproate, and lamotrigine in rapid cycling bipolar disorder | Q30985990 | ||
| Rapid versus non-rapid cycling as a predictor of response to olanzapine and divalproex sodium for bipolar mania and maintenance of remission: post hoc analyses of 47-week data | Q31013653 | ||
| The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor | Q33959664 | ||
| Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. | Q33966353 | ||
| The long-term course of rapid-cycling bipolar disorder | Q33968228 | ||
| Bipolar rapid cycling: focus on depression as its hallmark. | Q34317332 | ||
| Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT 2A receptors: functional receptor-binding and in vivo electrophysiological studies | Q34605085 | ||
| Bipolar disorder, obesity, and pharmacotherapy-associated weight gain. | Q35631515 | ||
| Mood state at study entry as predictor of the polarity of relapse in bipolar disorder | Q35985601 | ||
| Treatment of rapid-cycling bipolar disorder. | Q36618248 | ||
| Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo | Q38394215 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | placebo | Q269829 |
| bipolar I disorder | Q4915474 | ||
| P304 | page(s) | 679-687 | |
| P577 | publication date | 2008-03-25 | |
| P1433 | published in | International Journal of Clinical Practice | Q15758177 |
| P1476 | title | Aripiprazole monotherapy in patients with rapid-cycling bipolar I disorder: an analysis from a long-term, double-blind, placebo-controlled study | |
| P478 | volume | 62 |
| Q22242646 | A systematic review of the evidence on the treatment of rapid cycling bipolar disorder |
| Q34661499 | Almost all antipsychotics result in weight gain: a meta-analysis |
| Q37831357 | Aripiprazole for the treatment of bipolar disorder: a review of current evidence |
| Q57612470 | Aripiprazole in Bipolar Disorder |
| Q28478032 | Aripiprazole in the maintenance treatment of bipolar disorder: a critical review of the evidence and its dissemination into the scientific literature |
| Q37827219 | Aripiprazole: a clinical review of its use for the treatment of anxiety disorders and anxiety as a comorbidity in mental illness |
| Q37970762 | Aripiprazole: a review of its use in the management of mania in adults with bipolar I disorder |
| Q37299210 | Efficacy and safety of aripiprazole in the treatment of bipolar disorder: a systematic review |
| Q38012647 | Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry |
| Q34122946 | Emerging treatments in the management of bipolar disorder - focus on risperidone long acting injection. |
| Q35142737 | Korean Medication Algorithm Project for Bipolar Disorder: third revision |
| Q35822006 | Korean Medication Algorithm for Bipolar Disorder 2014: comparisons with other treatment guidelines. |
| Q37383679 | Metabolic risks in older adults receiving second-generation antipsychotic medication |
| Q37960184 | Recent advances in bipolar disorder pharmacotherapy: focus on bipolar depression and rapid cycling |
| Q92001769 | Recent advances in the biological treatment of mood disorders |
| Q57244624 | Recent progress in the pharmacotherapy of bipolar disorder |
| Q37517959 | Review of lithium effects on brain and blood |
| Q35862776 | Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders |
| Q49387505 | Spotlight on once-monthly long-acting injectable aripiprazole and its potential as maintenance treatment for bipolar I disorder in adult patients. |
| Q64330025 | TARC: Turkish aripiprazole consensus report- Aripiprazole use and switching from other antipsychotics to aripiprazole- consensus recommendations by a Turkish multidisciplinary panel |
| Q28066714 | The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm |
| Q26748677 | The Treatment of Adult Bipolar Disorder with Aripiprazole: A Systematic Review |
| Q34649187 | The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder |
| Q41528294 | Treatment and prevention of mania in bipolar I disorder: focus on aripiprazole |
| Q37665567 | Treatment of psychotic symptoms in bipolar disorder with aripiprazole monotherapy: a meta-analysis |
Search more.